Inicio>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>TH588 hydrochloride

TH588 hydrochloride

Catalog No.GC37777

El clorhidrato TH588 es el primer inhibidor de la familia de hidrolasas nudix de su clase que activa e inhibe potente y selectivamente el MTH1 (IC50 = 5 nM).

Products are for research use only. Not for human use. We do not sell to patients.

TH588 hydrochloride Chemical Structure

Cas No.: 1640282-30-9

Tamaño Precio Disponibilidad Cantidad
5mg
70,00 $
Disponible
25mg
130,00 $
Disponible
50mg
234,00 $
Disponible
100mg
422,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TH588 hydrochloride is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the MTH1 (IC50= 5 nM).

TH588 (2-10μM; 7-10 days) selectively and effectively kills U2OS, HeLa, MDA-MB-231, MCF-7, SW480, and SW620 cells with IC50s of 1.38, 0.83, 1.03, 1.08, 1.72, 0.8 μM [1]. Cell Viability Assay[1] Cell Line: U2OS, HeLa, MDA-MB-231, MCF-7, SW480, SW620, VH10, HDFn cells

TH588 (30 mg/kg; s.c.; once daily for 35 days) reduces tumour growth in SW480 xenograft cancer model[1]. Animal Model: 5-6 weeks female SCID mice (SW480 xenograft cancer model)[1]

[1]. Gad H, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014 Apr 10;508(7495):215-21.

Reseñas

Review for TH588 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TH588 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.